Dipyridamole in the nephritides.
A summary is given of the properties of dipyridamole and of the trials at the time this article was written that indicate its potential efficacy in the therapy of glomerulonephritides.
Wardle
E N
EN
D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use*; D004907:Erythrocyte Deformability / Q000187:drug effects; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole